Dr. Subbarao V. Mylavarapu, MD

Dr. Mylavarapu practices at Premier Cardiology Inc. in Newport Beach, California.

Dr. Mylavarapu's NPI, 1659330850, was assigned on March 17, 2006. Dr. Mylavarapu graduated from Guntur Medical College NTR in 1978. Dr. Mylavarapu holds California license A044935.

Dr. Mylavarapu's primary practice is Premier Cardiology Inc., at 520 Superior Ave, Newport Beach, CA 92663 in Orange County. The practice phone is (949) 478-7373.

Dr. Mylavarapu's primary practice is Premier Cardiology Inc. in Newport Beach, California. Dr. Mylavarapu is also affiliated with Hoag Hospital Newport Beach. The medical group on file is Premier Cardiology. Dmand AI also links Dr. Mylavarapu to 2 more hospitals, 1 physician office, 1 group practice or clinic and 1 other site, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mylavarapu practices, 6 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Mylavarapu's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dr. Mylavarapu is board certified in cardiovascular disease by the American Board of Internal Medicine. Dr. Mylavarapu is licensed in California.

CMS data shows 5,636 Medicare services from Dr. Mylavarapu across 46 procedure codes in 2024, for 1,775 Medicare patients. Medicare paid $582,262 for them.

CMS counts 1,775 Medicare patients who saw Dr. Mylavarapu in 2024. The largest group is 75 to 84, with 769 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 9% are also on Medicaid. Their average risk score is 1.60, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mylavarapu's median patient age at 76, with 47% women.

In 2024, Dr. Mylavarapu wrote 4,309 Medicare Part D claims for 614 patients. 79% of them were for generic drugs. CMS names the drug for 4,051 of them, across 54 drugs with 11 or more claims each, at $1,035,430 in total drug cost. In 2023, CMS named 3,841 claims across 49 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 33 out of 100 for Dr. Mylavarapu for performance year 2024, reported individually. Dr. Mylavarapu accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mylavarapu as offering telehealth. CMS counts 64 procedures of coronary angioplasty and stenting by Dr. Mylavarapu, more than 90% of the clinicians it reports for that procedure.

Leg revascularization (restoring blood flow): 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 1 paper to Dr. Mylavarapu. Dr. Mylavarapu's most frequent co-authors are Joseph S. Gelbfish, MD and Gerald Hollander, MD.

Dmand AI links Dr. Mylavarapu to 2 clinical trials. Conditions studied include Coronary Artery Disease and Coronary Disease.

CMS Open Payments shows 642 general payments to Dr. Mylavarapu from 60 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 75% of the total. CathWorks, Inc. paid the most, $103,479. It also lists 8 research payments totaling $127,800 from 2016 to 2022.

Dmand AI lists 1 award for Dr. Mylavarapu, most recently CMS Stage 1 EHR in 2013.

Dr. Mylavarapu graduated from Guntur Medical College NTR in 1978. Dr. Mylavarapu is a member of ACC.

Dr. Mylavarapu is in network with 9 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Humana. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.